• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

GPR30 介导的雌激素跨膜受体促进子宫内膜癌细胞系 RL95-2 的侵袭和癌变。

Estrogenic transmembrane receptor of GPR30 mediates invasion and carcinogenesis by endometrial cancer cell line RL95-2.

机构信息

Department of Obstetrics and Gynecology, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China.

出版信息

J Cancer Res Clin Oncol. 2012 May;138(5):775-83. doi: 10.1007/s00432-011-1133-7. Epub 2012 Jan 24.

DOI:10.1007/s00432-011-1133-7
PMID:22270964
Abstract

PURPOSE

The mechanisms underlying the effects of estrogen on endometrial cancer remain undefined. Although the classical mechanism of the action of estrogen involves binding to the estrogen receptors α and β, and transduction of the signal into the cell, G protein-coupled receptor (GPR) 30 has been shown to mediate nongenomic estrogen signaling. The goal of this study was to determine the role of GPR30 signal in the basic process such as invasion and carcinogenesis of endometrial cancer.

METHODS

We downregulated the expression of GPR30 in endometrial cancer cell line RL95-2 by transfection with shGPR30-pGFP-V-RS, a GPR30 antisense expression vector. The cells were then subjected to an MTT assay and a Transwell(®) migration assay. And an animal model was also used to investigate the influence of downregulation of GPR30 on oncogenesis.

RESULTS

Downregulation of GPR30 led to reduced growth and invasion by cells treated with 17β-estradiol. And the capacity of transfected RL95-2 cells to promote tumorigenesis was weakened in vivo.

CONCLUSIONS

Our data suggest that, for the endometrial cancer cell line RL95-2, GPR30 plays important roles in mediating the proliferative and invasive effects of estrogen and in tumorigenesis.

摘要

目的

雌激素对子宫内膜癌影响的作用机制尚不清楚。虽然雌激素作用的经典机制涉及与雌激素受体 α 和 β 结合,并将信号转导到细胞内,但已表明 G 蛋白偶联受体 (GPR)30 介导非基因组雌激素信号。本研究的目的是确定 GPR30 信号在子宫内膜癌基本过程(如侵袭和癌变)中的作用。

方法

通过用 shGPR30-pGFP-V-RS(GPR30 反义表达载体)转染 RL95-2 子宫内膜癌细胞系,下调 GPR30 的表达。然后将细胞进行 MTT 分析和 Transwell(®)迁移分析。还使用动物模型来研究下调 GPR30 对致癌作用的影响。

结果

下调 GPR30 导致用 17β-雌二醇处理的细胞生长和侵袭减少。并且转染的 RL95-2 细胞在体内促进肿瘤发生的能力减弱。

结论

我们的数据表明,对于子宫内膜癌细胞系 RL95-2,GPR30 在介导雌激素的增殖和侵袭作用以及肿瘤发生中起重要作用。

相似文献

1
Estrogenic transmembrane receptor of GPR30 mediates invasion and carcinogenesis by endometrial cancer cell line RL95-2.GPR30 介导的雌激素跨膜受体促进子宫内膜癌细胞系 RL95-2 的侵袭和癌变。
J Cancer Res Clin Oncol. 2012 May;138(5):775-83. doi: 10.1007/s00432-011-1133-7. Epub 2012 Jan 24.
2
The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.G 蛋白偶联受体 GPR30 介导了雌激素对子宫内膜癌细胞中 PI3K/Akt 通路激活的非转录效应。
Int J Gynecol Cancer. 2013 Jan;23(1):52-9. doi: 10.1097/IGC.0b013e31827912b8.
3
Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway.雌激素G蛋白偶联受体30信号通路通过丝裂原活化蛋白激酶(MEK/ERK)途径促进增殖、侵袭潜能和白细胞介素-6分泌,从而参与子宫内膜癌的调控。
Cancer Sci. 2009 Jun;100(6):1051-61. doi: 10.1111/j.1349-7006.2009.01148.x. Epub 2009 Mar 9.
4
Assessing Estrogen-Induced Proliferative Response in an Endometrial Cancer Cell Line Using a Universally Applicable Methodological Guide.使用通用方法指南评估子宫内膜癌细胞系中雌激素诱导的增殖反应。
Int J Gynecol Cancer. 2018 Jan;28(1):122-133. doi: 10.1097/IGC.0000000000001121.
5
Unveiling the molecular mechanisms of human platelet lysate in enhancing endometrial receptivity.揭示人血小板裂解物增强子宫内膜容受性的分子机制。
Hum Reprod. 2025 Jul 15. doi: 10.1093/humrep/deaf118.
6
Caveolin-1 inhibits the proliferation and invasion of lung adenocarcinoma via EGFR degradation.小窝蛋白-1通过表皮生长因子受体(EGFR)降解抑制肺腺癌的增殖和侵袭。
Sci Rep. 2025 Jul 1;15(1):21654. doi: 10.1038/s41598-025-05259-8.
7
N-myc downstream-regulated gene 1/Cap43 may function as tumor suppressor in endometrial cancer.N-myc 下游调节基因 1/Cap43 可能在子宫内膜癌中作为肿瘤抑制因子发挥作用。
J Cancer Res Clin Oncol. 2012 Oct;138(10):1703-15. doi: 10.1007/s00432-012-1249-4. Epub 2012 Jun 8.
8
The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer.G蛋白偶联雌激素受体(GPER/GPR30)可能作为早期宫颈癌的一种预后标志物。
J Cancer Res Clin Oncol. 2018 Jan;144(1):13-19. doi: 10.1007/s00432-017-2510-7. Epub 2017 Sep 18.
9
Retinoic Acid Receptor β: A Potential Therapeutic Target in Retinoic Acid Treatment of Endometrial Cancer.维甲酸受体β:维甲酸治疗子宫内膜癌的潜在治疗靶点。
Int J Gynecol Cancer. 2017 May;27(4):643-650. doi: 10.1097/IGC.0000000000000995.
10
Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα).雌二醇和他莫昔芬通过 GPR30 诱导子宫内膜癌细胞迁移,在低表达或不表达核雌激素受体 α(ERα)的情况下激活黏着斑激酶(FAK)。
PLoS One. 2013 Sep 9;8(9):e72999. doi: 10.1371/journal.pone.0072999. eCollection 2013.

引用本文的文献

1
The G Protein-Coupled Estrogen Receptor (GPER): A Critical Therapeutic Target for Cancer.G 蛋白偶联雌激素受体(GPER):癌症的关键治疗靶点。
Cells. 2023 Oct 16;12(20):2460. doi: 10.3390/cells12202460.
2
The combined signatures of G protein-coupled receptor family and immune landscape provide a prognostic and therapeutic biomarker in endometrial carcinoma.G 蛋白偶联受体家族与免疫图谱的联合特征可为子宫内膜癌提供预后和治疗的生物标志物。
J Cancer Res Clin Oncol. 2023 Nov;149(16):14701-14719. doi: 10.1007/s00432-023-05270-4. Epub 2023 Aug 16.
3
Role of Estrogen Receptor β, G-Protein Coupled Estrogen Receptor and Estrogen-Related Receptors in Endometrial and Ovarian Cancer.

本文引用的文献

1
Role of GPR30 in endometrial pathology after tamoxifen for breast cancer.他莫昔芬治疗乳腺癌后 GPR30 在子宫内膜病理中的作用。
Am J Obstet Gynecol. 2010 Dec;203(6):595.e9-16. doi: 10.1016/j.ajog.2010.07.034. Epub 2010 Oct 20.
2
G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells.在雌激素受体α阳性癌细胞中,G蛋白偶联受体30的表达受表皮生长因子(EGF)和转化生长因子α(TGFα)上调。
Mol Endocrinol. 2009 Nov;23(11):1815-26. doi: 10.1210/me.2009-0120. Epub 2009 Sep 11.
3
Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation.
雌激素受体β、G蛋白偶联雌激素受体及雌激素相关受体在子宫内膜癌和卵巢癌中的作用
Cancers (Basel). 2023 May 20;15(10):2845. doi: 10.3390/cancers15102845.
4
Cytoplasmic expression of G protein-coupled estrogen receptor 1 correlates with poor postoperative prognosis in non-small cell lung cancer.G蛋白偶联雌激素受体1的细胞质表达与非小细胞肺癌术后预后不良相关。
J Thorac Dis. 2022 May;14(5):1466-1477. doi: 10.21037/jtd-22-29.
5
Expression and Role of the G Protein-Coupled Estrogen Receptor (GPR30/GPER) in the Development and Immune Response in Female Reproductive Cancers.G 蛋白偶联雌激素受体(GPR30/GPER)在女性生殖系统癌症发展和免疫反应中的表达和作用。
Front Endocrinol (Lausanne). 2020 Aug 20;11:544. doi: 10.3389/fendo.2020.00544. eCollection 2020.
6
Chronic BDE-47 Exposure Aggravates Malignant Phenotypes and Chemoresistance by Activating ERK Through ERα and GPR30 in Endometrial Carcinoma.慢性暴露于BDE-47通过在子宫内膜癌中经由雌激素受体α(ERα)和G蛋白偶联受体30(GPR30)激活细胞外信号调节激酶(ERK)来加重恶性表型和化疗耐药性。
Front Oncol. 2019 Oct 31;9:1079. doi: 10.3389/fonc.2019.01079. eCollection 2019.
7
G Protein-Coupled Estrogen Receptor: A Potential Therapeutic Target in Cancer.G蛋白偶联雌激素受体:癌症中的一个潜在治疗靶点。
Front Endocrinol (Lausanne). 2019 Oct 25;10:725. doi: 10.3389/fendo.2019.00725. eCollection 2019.
8
Organs-On-Chip Models of the Female Reproductive System.女性生殖系统的芯片器官模型
Bioengineering (Basel). 2019 Nov 7;6(4):103. doi: 10.3390/bioengineering6040103.
9
MicroRNA‑195 inhibits epithelial‑mesenchymal transition by targeting G protein‑coupled estrogen receptor 1 in endometrial carcinoma.微小 RNA-195 通过靶向 G 蛋白偶联雌激素受体 1 抑制子宫内膜癌中的上皮-间充质转化。
Mol Med Rep. 2019 Nov;20(5):4023-4032. doi: 10.3892/mmr.2019.10652. Epub 2019 Sep 6.
10
Low Doses of Nonylphenol Promote Growth of Colon Cancer Cells through Activation of ERK1/2 via G Protein‒Coupled Receptor 30.低剂量壬基酚通过 G 蛋白偶联受体 30 激活 ERK1/2 促进结肠癌细胞生长。
Cancer Res Treat. 2019 Oct;51(4):1620-1631. doi: 10.4143/crt.2018.340. Epub 2019 May 15.
用一种新型他莫昔芬类似物刺激GPR30雌激素受体会激活SF-1并促进子宫内膜细胞增殖。
Cancer Res. 2009 Jul 1;69(13):5415-23. doi: 10.1158/0008-5472.CAN-08-1622. Epub 2009 Jun 23.
4
Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway.雌激素G蛋白偶联受体30信号通路通过丝裂原活化蛋白激酶(MEK/ERK)途径促进增殖、侵袭潜能和白细胞介素-6分泌,从而参与子宫内膜癌的调控。
Cancer Sci. 2009 Jun;100(6):1051-61. doi: 10.1111/j.1349-7006.2009.01148.x. Epub 2009 Mar 9.
5
Expression of G protein-coupled receptor 30 in the hamster ovary: differential regulation by gonadotropins and steroid hormones.G蛋白偶联受体30在仓鼠卵巢中的表达:促性腺激素和甾体激素的差异调节
Endocrinology. 2007 Oct;148(10):4853-64. doi: 10.1210/en.2007-0727. Epub 2007 Jul 19.
6
Hormones and cancer.激素与癌症。
Cell Res. 2007 Apr;17(4):277-9. doi: 10.1038/cr.2007.26.
7
Identification and developmental changes of aromatase and estrogen receptor expression in prepubertal and pubertal human adrenal tissues.青春期前和青春期人类肾上腺组织中芳香化酶和雌激素受体表达的鉴定及发育变化
J Clin Endocrinol Metab. 2007 Jun;92(6):2215-22. doi: 10.1210/jc.2006-2329. Epub 2007 Apr 3.
8
GPR30: a novel indicator of poor survival for endometrial carcinoma.GPR30:子宫内膜癌患者生存率低的一种新指标。
Am J Obstet Gynecol. 2007 Apr;196(4):386.e1-9; discussion 386.e9-11. doi: 10.1016/j.ajog.2007.01.004.
9
G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.G蛋白偶联受体30(GPR30)介导卵巢癌细胞中基因表达的变化以及对17β-雌二醇和选择性GPR30配体G-1的生长反应。
Cancer Res. 2007 Feb 15;67(4):1859-66. doi: 10.1158/0008-5472.CAN-06-2909.
10
Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.七跨膜雌激素受体GPR30在原发性乳腺癌中的分布及其与肿瘤进展的临床病理决定因素的关联。
Clin Cancer Res. 2006 Nov 1;12(21):6359-66. doi: 10.1158/1078-0432.CCR-06-0860.